Research Analysts Offer Predictions for Y-mAbs Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities researchers at Wedbush cut their Q3 2024 EPS estimates for shares of Y-mAbs Therapeutics in a research note issued to investors on Monday, August 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.15) per share for the quarter, down from their prior forecast of ($0.14). Wedbush currently has a “Outperform” rating and a $23.00 price target on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.58) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.94) EPS.

A number of other equities analysts have also weighed in on YMAB. Cantor Fitzgerald started coverage on Y-mAbs Therapeutics in a research report on Friday. They set an “overweight” rating and a $20.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday. Truist Financial began coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 target price for the company. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday. Finally, BMO Capital Markets cut their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Y-mAbs Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $19.38.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ:YMAB opened at $12.24 on Thursday. The firm has a market cap of $545.54 million, a P/E ratio of -25.45 and a beta of 0.66. Y-mAbs Therapeutics has a 52-week low of $4.69 and a 52-week high of $20.90. The business’s 50 day simple moving average is $11.84 and its two-hundred day simple moving average is $13.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The company had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. During the same period last year, the company earned ($0.14) EPS.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently added to or reduced their stakes in YMAB. Campbell & CO Investment Adviser LLC purchased a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $562,000. Federated Hermes Inc. grew its holdings in Y-mAbs Therapeutics by 4,708.0% during the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock valued at $303,000 after purchasing an additional 43,549 shares during the period. Sapient Capital LLC purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth $298,000. SG Americas Securities LLC raised its stake in shares of Y-mAbs Therapeutics by 17.5% in the fourth quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after buying an additional 3,210 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Y-mAbs Therapeutics by 4.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock valued at $178,000 after buying an additional 1,089 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the sale, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the transaction, the insider now directly owns 197,681 shares in the company, valued at $2,378,102.43. The disclosure for this sale can be found here. Insiders have sold 99,444 shares of company stock valued at $1,203,925 over the last ninety days. Corporate insiders own 21.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.